AR119033A1 - Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa - Google Patents

Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa

Info

Publication number
AR119033A1
AR119033A1 ARP200101512A ARP200101512A AR119033A1 AR 119033 A1 AR119033 A1 AR 119033A1 AR P200101512 A ARP200101512 A AR P200101512A AR P200101512 A ARP200101512 A AR P200101512A AR 119033 A1 AR119033 A1 AR 119033A1
Authority
AR
Argentina
Prior art keywords
histone deacetylase
individual
hdaci
methods
deacetylase inhibitors
Prior art date
Application number
ARP200101512A
Other languages
English (en)
Inventor
Robert Mrae
Gail L Brown
David Slack
Marshelle Smith Warren
Richard Trauger
Xiaohu Deng
Original Assignee
Viracta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viracta Therapeutics Inc filed Critical Viracta Therapeutics Inc
Publication of AR119033A1 publication Critical patent/AR119033A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describen ciertos montos y calendarios de dosificación que evitan y gestionan de manera eficaz los efectos colaterales asociados con el tratamiento con inhibidores de la histona deacetilasa. Opcionalmente, estos calendarios y regímenes de dosificación incluyen tratamiento con una agente antiviral. Reivindicación 1: Un método para tratar el cáncer en un individuo, el método comprendiendo la administración al individuo de: (a) una cantidad eficaz de un inhibidor de la histona deacetilasa (HDACi), caracterizado porque el HDACi está caracterizado por una semivida de eliminación menor que 30 horas; y (b) una cantidad eficaz de un fármaco antiviral; donde el individuo es tratado conforme a un calendario de tratamiento, donde al individuo no se le administra el HDACi por al menos una dosis del calendario de tratamiento.
ARP200101512A 2019-05-31 2020-05-28 Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa AR119033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962855454P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
AR119033A1 true AR119033A1 (es) 2021-11-17

Family

ID=73552282

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101512A AR119033A1 (es) 2019-05-31 2020-05-28 Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa

Country Status (5)

Country Link
AR (1) AR119033A1 (es)
CL (1) CL2021003170A1 (es)
TW (1) TW202110452A (es)
UY (1) UY38720A (es)
WO (1) WO2020243326A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006741A (es) 2019-12-05 2022-06-14 Viracta Subsidiary Inc Formas de estado solido del inhibidor de hdac.
KR20230097098A (ko) 2020-10-28 2023-06-30 비락타 서브시디어리 인크. Hdac 억제제 고체 상태 형태
WO2024086688A1 (en) * 2022-10-21 2024-04-25 Viracta Subsidiary, Inc. Dosing methods for hdac inhibitor compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676521B2 (en) * 2014-07-21 2020-06-09 The Rockefeller University Combination of broadly neutralizing HIV antibodies and viral inducers
EP3310168A4 (en) * 2015-06-19 2019-03-06 Trustees of Boston University METHODS AND COMPOSITIONS FOR TREATING CONDITIONS INDUCED BY HERPETIC VIRUS

Also Published As

Publication number Publication date
CL2021003170A1 (es) 2022-07-15
WO2020243326A1 (en) 2020-12-03
TW202110452A (zh) 2021-03-16
UY38720A (es) 2020-12-31

Similar Documents

Publication Publication Date Title
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
PE20190351A1 (es) Agente terapeutico del sindrome de hunter y metodo de tratamiento
JP2016515586A5 (es)
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112019002461A2 (pt) regime de dosagem para tratamento de tumores sólidos
EA202193276A1 (ru) Способы лечения холангиокарциномы
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
RU2017105837A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией, с применением цис-кломифена
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR122954A1 (es) Composiciones para tratamiento de atrofia muscular espinal